Company Profile Lundbeck

Lundbeck is a global pharmaceutical company conducting research into, developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, bipolar disorder, Alzheimer’s disease, Parkinson’s disease, Huntington's disease, epilepsy, stroke and insomnia.
The company was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Today the company is among the biggest Danish companies.

Lundbeck is one of Denmark’s most research-intensive enterprises.  A total of 1,400 highly-trained specialists are employed in the research and development units.  Each year, Lundbeck ploughs back around 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from neurological disorders.

Lundbeck markets a number of different pharmaceuticals for the treatment of disorders of the central nervous system (CNS). The most recently launched compounds include: Cipralex/Lexapro (depression), Ebixa (Alzheimer’s disease), Azilect (Parkinson’s disease), Xenazine (chorea associated with Huntington's disease), Serdolect (schizophrenia) and Sabril (epilepsy), Sycrest/Saphris (schizophrenia, bipolar disorder). 

The company employs 5.900 people worldwide, 2.000 of whom are based in Denmark. The  products are registered in more than 100 countries. Lundbeck has production facilities in Italy, France, Mexico and Denmark and research centres in Denmark and the USA.
In 1999, Lundbeck’s shares were listed on the Copenhagen Stock Exchange. The Lundbeck Foundation, which distributes more than DKK 300 million in grants for various types of research each year, owns about 70% of the shares in Lundbeck, while the remaining 30% are traded on the stock exchange.

http://www.lundbeck.com